ArticleDrug design, development and therapy2019
Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies.Frontiers in psychiatry · 2022Pooled it
- Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis.Journal of clinical pharmacology · 2026Article
- Tailoring cariprazine for dual disorders via secondary pharmacophore optimization.European journal of medicinal chemistry · 2026Article
- Physiologically-Based Pharmacokinetic Model-Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors.CPT: pharmacometrics & systems pharmacology · 2026Article
- Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008-2024).Neuroscience applied · 2025Review
- Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report.BMC psychiatry · 2023Article
- The improvement of motor symptoms in Huntington's disease during cariprazine treatment.Orphanet journal of rare diseases · 2023Article
- Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal.Biomedicines · 2023Review
- Dopamine DJournal of medicinal chemistry · 2023Article
- The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders.Frontiers in psychiatry · 2023Article
- Antipsychotic-induced bone loss: the role of dopamine, serotonin and adrenergic receptor signalling.Frontiers in cell and developmental biology · 2023Review
- Evaluation of the Effect of Cariprazine on Memory and Cognition in Experimental Rodent Models.International journal of environmental research and public health · 2022Article
- Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?CNS drugs · 2022Article
- Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method.Molecules (Basel, Switzerland) · 2022Article
- Case Report: Long-Acting Oral Cariprazine.Frontiers in psychiatry · 2022Article
- Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine DFrontiers in psychiatry · 2022Review
- Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?World journal of psychiatry · 2021Review
- Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.Advances in therapy · 2021Review
- GW117: A novel serotonin (5-HTCNS neuroscience & therapeutics · 2021Article
- Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCariprazine, a dopamine D
methodsIn vitro receptor binding and functional assays, electrophysiology, animal models, microdialysis, and kinetic-metabolism approaches were used to characterize the pharmacology of DCAR and DDCAR.
resultsSimilar to cariprazine, both metabolites showed high affinity for human D
conclusionOverall, in vitro and in vivo pharmacological profiles of DCAR and DDCAR demonstrated high similarity with cariprazine, suggesting that the major metabolites of cariprazine contribute significantly to its clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.